CN109207524A - The foundation and application of human obesity's zebra fish model based on FTO gene - Google Patents
The foundation and application of human obesity's zebra fish model based on FTO gene Download PDFInfo
- Publication number
- CN109207524A CN109207524A CN201710545564.7A CN201710545564A CN109207524A CN 109207524 A CN109207524 A CN 109207524A CN 201710545564 A CN201710545564 A CN 201710545564A CN 109207524 A CN109207524 A CN 109207524A
- Authority
- CN
- China
- Prior art keywords
- fto
- zebra fish
- gene
- human obesity
- screening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000252212 Danio rerio Species 0.000 title claims abstract description 81
- 101150076348 FTO gene Proteins 0.000 title claims abstract description 79
- 208000008589 Obesity Diseases 0.000 title claims abstract description 42
- 235000020824 obesity Nutrition 0.000 title claims abstract description 39
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 54
- 230000035772 mutation Effects 0.000 claims abstract description 34
- 108091033409 CRISPR Proteins 0.000 claims abstract description 32
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 21
- 238000012216 screening Methods 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000009825 accumulation Methods 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 238000003209 gene knockout Methods 0.000 claims abstract description 5
- 241000251468 Actinopterygii Species 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 230000014509 gene expression Effects 0.000 claims description 4
- 230000004720 fertilization Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 108700008625 Reporter Genes Proteins 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 108700024526 zebrafish sox32 Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 abstract description 15
- 238000004458 analytical method Methods 0.000 abstract description 10
- 238000013461 design Methods 0.000 abstract description 8
- 238000012790 confirmation Methods 0.000 abstract description 6
- 238000005520 cutting process Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108700028369 Alleles Proteins 0.000 description 15
- 238000012163 sequencing technique Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 238000010586 diagram Methods 0.000 description 12
- 210000001161 mammalian embryo Anatomy 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 235000013601 eggs Nutrition 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000012408 PCR amplification Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 230000013020 embryo development Effects 0.000 description 6
- 230000005782 double-strand break Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 101100403108 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mud1 gene Proteins 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101150072078 aktip gene Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 231100000221 frame shift mutation induction Toxicity 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 230000013190 lipid storage Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000448255 Congiopodus peruvianus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000007683 Pediatric Obesity Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical class [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 235000011091 sodium acetates Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100001265 toxicological assessment Toxicity 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/40—Fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Animal Husbandry (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to the foundation and application of human obesity's zebra fish model based on FTO gene, specific steps include the exon design CRISPR sequence for zebra fish fto gene encoded key functional domain, screening confirmation can effectively guide the active sgRNA of Cas9 cutting target gene, then active sgRNA is used, prepare the first person of building of fto gene knockout, sexal maturity is grown to just not build person, enables its pangamy, generates F1 generation；By the genotype identification to F1 individual, the zebra fish mutant of fto gene knockout is screened；Pass through the analysis to fto homozygous mutation, the afunction of establishment fto is beneficial to the reduction of the accumulation of fat of zebra fish prelarva, the zebra fish model of the human obesity based on fto gene is established, and then fto can be applied to screening as mark gene and establish the novel drugs and new method for the treatment of human obesity.
Description
Technical field
The invention belongs to field of biotechnology, and being related to screening determination can carry out genome editor's to zebra fish fto gene
The preferred embodiment that sgRNA sequence, preparation zebra fish to gene target are mutated, and using zebra fish fto as significant gene
The application of the zebra fish model of screening treatment human obesity disease drug.
Technical background
Obesity is that fat accumulation extra in vivo is more than to cause the energetic supersession of puzzlement unbalance human health to a certain degree
Chronic disease.People use BMI (body mass index, body mass index) usually to judge whether individual is fat.Because body fat increases
Adding makes weight be above standard weight 20% or body mass index [BMI=weight (Kg)/(height)2(m2)] it is known as obesity greater than 24
Disease.Obesity will increase the illness probability of Other diseases, especially heart disease, type-2 diabetes mellitus, obstructive sleep respiratory distress, cancer
The diseases such as disease and osteoarthritis.In recent decades, obesity patient increases at an amazing speed in the world.Especially
Virgin, Adolescent Obesity increases increasingly swift and violent (1,2).In 2014, there are about 6,000,000 adults (13%) and forty-two million 5 years old or less
Children suffer from obesity.Obesity is considered as 21 century unhealthful disease the most serious.
The fat cause of disease is broadly divided into external cause and internal cause, and external cause is with hyperphagia, and based on Lack of Movement, caloric intake is extra
Heat consumption increases Fatty synthesis by (3,4).And internal cause is if due to caused by genetic predisposition.Similar to other many
Disease, obesity are the results to interact between inherent cause and environmental factor.The morbidity of the simple obesity of the mankind has centainly
Genetic background.Polymorphism existing for many genes controls appetite and metabolism to be easier to make body in the presence of enough energy
Increase to be liable to obesity again.Show the common bariatric patient of 40-70% in family and twinborn research
It is fat (5,6) to belong to heredity.By the end of 2006, it has been found that on human genome with obesity-related polymorphic site
Already exceed 41.2008, the mankind filtered out first gene FTO (fat mass that can lead to human obesity disease
and obesity associated gene).Loos discovery, FTO is an obesity-prone gene, and FTO gene first includes
Some mutation of son are positively correlated with obesity.The study found that FTO gene First Intron carries the homozygous crowd's of obesity SNP
Weight is 3-4kg averagely heavier than the crowd for not carrying SNP, and the risk for suffering from obesity will increase by 1.67 times (7).Other one
About showing that FTO existing some SNP sites in First Intron are close with type-2 diabetes mellitus disease in the report of FTO
(8) are closed in cut phase.But by control patient BMI index, it is found that the diabetic phenotype of these patients disappears, this explanation, the mutation of FTO
It is to influence secondary diabetes conditions by influencing weight.These are statistics indicate that the mutation of FTO gene is close with obesity
Cut phase is closed.
In molecular biology level, in mouse, xenopous laevis, zebra fish, drosophila and nematode isotype animal is raw
Object event and people enjoy identical molecular mechanism.Therefore, the effective in body mould of human diseases can be made using model animal
Type.In all model animals, zebra fish is the bridge connected between invertebrate and mammalian animal model, in human gene
87% can find homologous gene wherein.It selects to move using zebra fish as mode currently, the whole world has more than 1000 laboratories
Object carries out the research from the different research fields such as fundamental biological knowledge, Environmental Toxicological Assessment to medicament research and development, and the country has more than 100
Laboratory is using zebra fish as main study subject.Zebra fish raising is simple, and feeding environment control is more in certain egg laying amount, and every time one
It can lay eggs 200-300 pieces weekly to fish, embryonic development is transparent, and growth cycle is shorter, is to carry out embryonic development mechanism, genome
The good material of research and pathogenic mechanism research.For the tumor susceptibility gene FTO closely related with human obesity, people's FTO base
Because being located at No. 16 chromosome, FTO albumen is made of 505 amino acid；And in zebra fish, with people's FTO homologous gene fto
In No. 7 chromosomes of zebra fish, albumen is made of 579 amino acid.Bioinformatic analysis discovery, fto gene and people's FTO base
Because of ortholog (there are co-linear relationships with aktip and AKTIP gene respectively).In its expression product protein
Amino acid composition on, it is found that the phase same sex (identity) of FTO and fto is high, two functional domains (are FTO catalysis respectively
Domain and FTO C- terminal domain) the phase same sex is higher, and further support FTO gene highly conserved in people and zebra fish.It is based on
The above reason, we use zebra fish for model, using genome editing technique, targeting mutation fto gene.Mutant is divided
Analysis discovery, the homozygous mutation of fto cause fat cell to substantially reduce in the intracorporal accumulation of zebra fish.The result shows that fto is one
With obesity-related gene, the mark gene of screening treatment obesity may be used as.
Bibliography:
1.Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, et al., Obesity
And the metabolic syndrome in children and adolescents.N Engl J Med.2004,350
(23):
2.Fleisch AF, Agarwal N, Roberts MD, Han JC, Theim KR, et al., Influence of
serum leptin on weight and body fat growth in children at high risk for adult
Obesity.J Clin Endocrinol Metab.2007,92 (3): 948-954.
3.Abelson P, Kennedy D.The obesity epidemic.Science 2004；304:1413.
4.Keith SW, Redden DT, Katzmarzyk PT, Boggiano MM, Hanlon EC, et al.,
Putative contributors to the secular increase in obesity:exploring the roads
less traveled.Int J Obes 2006；30:1585-1594.
5.Maes HH, Neale MC, Eaves LJ.Genetic and environmental factors in
relative body weight and human obesity. Behav Genet 1997；27:325-351.
6.Clement K, Sorensen TIA.Obesity:Genomics and Postgenomic.Informa
Healthcare:New York, 2008.
7.Loos, R.J., and Bouchard, C.FTO:the first gene contributing to common
Forms of human obesity.Obesity reviews:an official journal of the
International Association for the Study of Obesity 2008；9,246-250.
8.Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, et al., A
common variant in the FTO gene is associated with body mass index and
predisposes to childhood and adult obesity.Science 2007；316:889-894.
Summary of the invention
For the zebra fish model for establishing human obesity, we are struck using the targeting of CRISPR/Cas9 genome editing technique
Except fto gene, the influence that obesity of the fto gene pairs characterized by fat accumulation occurs is confirmed.CRISPR/Cas9 technology is
It is no successfully to edit fto gene, realize the gene knockout of zebra fish fto, key, which is whether to screen, effectively to be guided
Cas9 identifies the sgRNA of target gene sequence (CRISPR sequence).When sgRNA can effectively guide Cas9 targets identification target base
Cause, Cas9 therein can cut off 3 ' -5 ' phosphodiester bonds between 3 to 4 nucleotide before the PAM of CRISPR sequence, from
And form the double-strand break (DSB) of genomic DNA.Once DSB is formed, embryonic cell will start non-homologous end joining reparation or
Micro- homologous end connects repair mechanism, as a result the DSB of revision points group introduces insertion and deletion (Indel) mutation at DSB.It is logical
It crosses and screens the mutant for carrying and having frameshift mutation gene in F1 generation, so that it may the zebra fish mutant for obtaining fto gene knockout, from
And it is expected to understand effect of the fto in obesity generation.To realize this target, we, will according to the analysis of the functional domain of Fto
CRIPSR sequence design is on the 3rd exon corresponding to first functional domain.We devise 8 CRISPR sequence (tables altogether
One).According to above-mentioned CRISPR sequence, we are prepared for corresponding sgRNA (sgRNA1 to sgRNA8).With microinjection skill
Art, 8 sgRNA of acquisition are divided into two groups, and (sgRNA1, sgRNA3, sgRNA5 and sgRNA7 are group 1；sgRNA2,sgRNA4,
SgRNA6 and sgRNA8 is 2) group, into zebra fish fertilized egg, carries out the sgRNA with Cas9 albumen co-injection respectively
Activity verifying.Cas9 can be effectively guided to identify target as a result, present invention firstly provides two according to activity verifying
The sgRNA1 and sgRNA3 of CRISPR sequence.
SgRNA1 and sgRNA3 and Cas9mRNA are injected into zebra fish fertilized egg (F0), embryonic development to be injected to property at
When ripe, its pangamy is enabled, obtains F1 individual, by clip tail fin, genotype identification is carried out to F1 individual.It reflects according to genotype
It is fixed as a result, invention further provides the preparation methods for the zebra fish mutant for carrying fto knock out mutants.
When F1 heterozygote grows to sexal maturity, F1 is selfed, obtains F2 for embryo.To embryonic development to after fertilization 4 days
(4dpf) carries out staining analysis to embryo with oil red, according to analysis result, it has been found that when zebra fish fto afunction,
The fat accumulation amount of embryo is remarkably decreased.The present invention provides human obesity's mould based on zebra fish fto gene again as a result,
Type, zebra fish fto can be used as the marker gene of screening obesity treating medicine, can make any substance of fto expression decline
It will be provided with inhibiting the effect of obesity.
Detailed description of the invention
The conserved structure function domain analysis of Fig. 1 zebra fish Fto protein.Fto includes two conserved functional domains, respectively
FTO_NTD superfamily and FTO_CTD superfamily.
Fig. 2 can effectively guide the sgRNA activity verifying analysis of Cas9 targeting cutting fto gene.Utilize VectorNTI software
(totally 10 recons) is compared to recon sequencing sequence, shows that sgRNA1 and sgRNA3 are active, and sgRNA1
Activity rate is that 20%, sgRNA3 activity rate is 10%.
The verifying analysis of Fig. 3 sgRNA2/4/6/8 activity.Recon sequencing sequence is compared using Vector NTI software
SgRNA2, sgRNA4, sgRNA6, sgRNA8 are inactive or active lower to be shown to analysis (totally 10 recons).
The sequencing peak figure of the fto mutation allele partial sequence of Fig. 4 zebra fish F1 generation mutant 3 carryings
The truncated protein structural representation of the fto mutation allele predictive coding of Fig. 5 zebra fish F1 generation mutant 3 carryings
Figure.WT: wild type Fto protein structure schematic diagram, MUT1: the protein of one of fto mutation allele predictive coding
Structural schematic diagram, the protein structure schematic diagram of MUT2: the second fto mutation allele predictive coding.
The sequencing peak figure of the fto mutation allele partial sequence of Fig. 6 zebra fish F1 generation mutant 11 carryings.
The truncated protein structure of the fto mutation allele predictive coding of Fig. 7 zebra fish F1 generation mutant 11 carryings is shown
It is intended to.WT: wild type Fto protein structure schematic diagram, MUT1: the egg of predictive coding after one of fto allelic mutation
White matter structural schematic diagram.
The sequencing peak figure of the fto mutation allele partial sequence of Fig. 8 zebra fish F1 generation mutant 13 carryings.
The truncated protein structure of the fto mutation allele predictive coding of Fig. 9 zebra fish F1 generation mutant 13 carryings is shown
It is intended to.Wild type Fto protein structure schematic diagram, MUT1: the protein of predictive coding after one of fto allelic mutation
Structural schematic diagram.
The zebra fish mutant prelarva inner lipid storage capacity that Figure 10 carries fto homozygous mutation is reduced.Oil red O is to development to 4
It zebra fish prelarva is dyed, and finds compared with wild-type zebrafish, fto mutant zebra fish prelarva body fat contains
Amount significantly reduces.
Specific embodiment
Experimental method in embodiment is unless otherwise specified conventional method.
The screening of 1 activity sgRNA of embodiment
(1) design of the CRISPR of targeting mutation zebra fish fto gene
1, gene information is analyzed
The CDS of 1.1 coding zebra fish fto genes
ATGAAACCGAGGCAGCGTAAACAGTACTTCAGGAACATGAAAAGATCGGATGACAGTGAGAGGGAAAAGAGGAGAA
AGAGGCGAAGGCTTCTACAGGAACTAGGAGAGCAGAGGATTCCATATCTTTCCCCAACAGACCCAGGATTTCAGGA
CCTGTGGGACTCCAGTTATGCGGGCCTGGCTTTGCGGCAGTCTGGTACCCTTCCAGAAGGTCTCCATGAGAAGGTT
CAATCTGCTCTGTTAACTCTACAGCGGCATGGATGTCTCCTCCGAGATCTTGTCCGAGTTCGAGACCGGGACGTCT
TCACGGCCGTTTCACGCGCTCTCGTGGGTCAGCCGGGCTACACGTACCGTTATCTGGACACTCGTCTGTTCACCAT
CCCCTGGCACTGTGAAGGAGAAGAGGGCCAGAAAGATGAGAAAGGCAAACCTTGCTGTGACTCCGACCTGAGGGAC
GCTTGTAAAGCATTATGGGAGCTCAATCAGTTCTTTTGCTCGGATGTAAAGCAGCAGACAAATGCAAGAGGTGTCA
AGCGTACCCGCAGTGACACTGAAAACAGCGAAGATGCGCCAGGGGAGGGAATGTGCGAAGAAGAGAGTGTTAAGGA
CAGGTTAGTTGAGGAGAAAACCATAGAGGAGGAGGAGGAAGACAGTGGACAGGGCTGCTCTCATTCCTCACCTCCT
TCATCCACTCCGCCAGCTGCTCAGGCCAGCCTGGTTCAGTTTAACGTCACGCTAATCAACTACATGAACCCTGCAG
CCATGACCCAGCTGAAGGAAGAGCCATATTACGGCATGGGCAAAATGGCAGTCGGTTGGCATCATGATGAGAACCT
GGTTCCTCTCTCACCAGTTGCCGTTTACAGCTATAGCTGCCCAGCAGAGCCAAAGAATGAAGGAGTTACTGAGAAA
GACGGGGAGGGAAAGAGCAAAGAAAAAGAAAGAGAGGCCAAAGGTGAAGGAACAAGTACAGAAGAAGTGAAGAAAG
AAGGAGAAGCTTCGGTGAAGGAGGACGTGGAAAAAGAGAAGACGTGTTGGCGAGTTGGTCTGAAGGTGGCCTGGGA
CATCCACACACCAGGTCTGGCTTTGCCTCTCCAATCTGGAGACTGCTACTATATGACAGATGATCTGAACCGGACA
CATCAGCACTGTGTACTGGCTGGTGACACAGCTAGATTCAGCTCAACTCACAGAGTCGCACAGTGTTGTACGGGTA
CACTGGACTACATACAGAAACGTTGCTCTGAGGCCTTGGAGAATTTACACAGCGACCCCGAGAAGAACGCCAAGAG
CCTGATTTCCCTCCTGCCCTCCATCCTCCAACGCATTGAGGATATCCACAACGAGGTGGAGTTTGAGTGGCTGAGG
CAGTACTGGTTCCAGGGCCGGCGTTACGCTCGATTCTGCAGCTGGTGGACTAAACCCATGGAGCAGATGGAGAAAG
ATTGGAAGGAAATGGAGAGAATGACTCAGCTGCTGTTGGTGGTGGTTGAGGATGAGGCCACGGCACAGGAGAACAG
AAGAGAGATGGCAGACGTGTTACTAAATGCGCTGACCGACAGACAGCAGCACAGACAGACATGGAGAGACAGATGC
CAGTCCAGCCTGGCGCAGACTTTGCCCCCTGAGGAAGCACCTGTGGACAGACCCTATTGGAGCAATGATGATCCTG
ACATGCCCCTCCCCTTTGACCTCTCTGACATCATCAACCGCGTTGAGTCGCTTCTATGGAGAATGTAA
1.2 zebra fish Fto protein sequences
The conserved structure functional domain of 1.3 protein
See Fig. 1.
2, the design of CRISPR
The exon 3 sequence of 2.1 zebra fish fto genes
Yellow font is the CRISPR of design.The sequence of underscore is PAM sequence NGG (RC:CCN).
The CRISPR design of table one, targeting mutation zebra fish fto gene
(2) the active identification of sgRNA of targeting mutation zebra fish ucp1 gene
1, the genotype identification of target gene
1.1 target gene group sequences to be amplified
Yellow highlight mark is the CRISPR of design, is PAM sequence NGG (RC:CCN) with underscore, the highlighted mark of green
It is denoted as primer sequence.
The design of primers of 1.2PCR amplification
| Sequence names | Sequence | Purposes |
| F-Fto-1 | caaaaaccagtaggtctgtgga | PCR forward primer |
| R-Fto-1 | Ggctgcagggttcatgtagt | PCR reverse primer |
2, the external synthesis of sgRNA
The preparation (PCR method) of 2.1sgRNA template
2.1.1PCR primer
Forward primer sequence is as follows:
Note: the high bright part of grey is that T7 starts subdivision, and underscore part is the CRISPR sequence of customization, small letter
Mother is part sgRNA skeleton template sequence.
Reverse primer (for universal primer) R-Common:AAAAAAAGCACCGACTCGGTGCCAC
2.1.2 template sequence is transcribed in vitro in the estimated sgRNA obtained
Note: the high bright part of grey is that T7 starts subdivision, and underscore part is the CRISPR sequence of customization, small letter
Mother is sgRNA skeleton template sequence.
The in-vitro transcription of 2.2sgRNA
2.2.1 process is transcribed in vitro
Above-mentioned template after purification is transcribed in vitro with t7 rna polymerase.Use RNA in-vitro transcription kit
(MAXIscript SP6/T7, Ambion, USA), sequentially adds 10 × Transcription by kit specification requirement
Buffer 2μl、10mM ATP 1μl、10mM CTP 1μl、10mM GTP 1μl、10mM UTP 1μl、T7RNA
2 μ l of polymerase mix, 12 μ l of template DNA, after flicking mixing centrifugation, 37 DEG C of water-bath 1h.
DNase I (Ambion, USA) 1 μ l, 37 DEG C of water-bath 15min, to remove removing template is added.
30 μ l DEPC water extended volumes to 50 μ l are added later, while 5 μ l nuclease free 3M sodium acetates (pH5.2) are added
With the dehydrated alcohol (domestic analysis is pure) of 3 times of volumes, -80 DEG C of precipitates overnights.4 DEG C of 12,000g are centrifuged 20min, after removing supernatant,
It is deposited in draught cupboard to dry, it is spare to be stored in -80 DEG C of refrigerators after being then resuspended with 15 μ l nuclease free ultrapure waters.
2.2.2sgRNA sequence
Fto-sgRNA1:
GGACUCCAGUUAUGCGGGCCGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAA
AAGUGGCACCGAGUCGGUGCUUUUUUU
Fto-sgRNA2:
GAGCAGAUUGAACCUUCUUAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAA
AAGUGGCACCGAGUCGGUGCUUUUUUU
Fto-sgRNA3:
GAACUCGGACAAGAUCUCGGGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAA
AAGUGGCACCGAGUCGGUGCUUUUUUU
Fto-sgRNA4:
GGGCUACACGUACCGUUAUCGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAA
AAGUGGCACCGAGUCGGUGCUUUUUUU
Fto-sgRNA5:
GAGGGCCAGAAAGAUGAGAAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAA
AAGUGGCACCGAGUCGGUGCUUUUUUU
Fto-sgRNA6:
GCUCAAUCAGUUCUUUUGCUGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAA
AAGUGGCACCGAGUCGGUGCUUUUUUU
Fto-sgRNA7:
GAAAACAGCGAAGAUGCGCCGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAA
AAGUGGCACCGAGUCGGUGCUUUUUUU
Fto-sgRNA8:
GGAGGAGGAAGACAGUGGACGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAA
AAGUGGCACCGAGUCGGUGCUUUUUUU
3, Cas9 albumen
The Cas9 albumen bought from commercial company (spun gold is auspicious) is diluted to 400ng/ μ l with DEPC water, be placed in after packing-
It is saved in 20 DEG C of refrigerators.
4, the microinjection of zebra fish fertilized egg
Zebra fish fertilized egg is collected according to a conventional method.Above-mentioned sgRNA1, sgRNA3, sgRNA5, sgRNA7 is (final concentration of
50ng/ μ l)/sgRNA2, sgRNA4, sgRNA6, sgRNA8 (final concentration of 50ng/ μ l) and Cas9 albumen it is (final concentration of
200ng/ μ l) mixing after, micro- injection zebra fish fertilized egg, injection volume be the every embryo of 1nl.
5, the recombination confirmation of target gene editor sub (Edits)
The preparation of 5.1 target gene group fragment templates
When embryonic development to be injected is to pf for 24 hours, 5 pieces of embryos are respectively taken, " the zebra fish genotype identification for using our company to produce
Kit " prepare genomic DNA template, specific reaction condition are as follows: 65 DEG C of 30min, 95 DEG C of 5min, 16 DEG C of 1min, 4 DEG C
5.2PCR amplification reaction system (20 μ l)
2 × Mastermix (Transgene), 10 μ l, the ultrapure water of 7 μ l, 1 μ l forward and reverse (F1-lgmn and R1-lgmn)
The genomic DNA template of primer (5 μM) and 1 μ l prepared by 1.6.5.1.
5.3PCR reaction condition
95 DEG C of 3min, 30 × (95 DEG C of 30s, 56 DEG C of 30s, 72 DEG C of 1min), 72 DEG C of 10min, 4 DEG C.
The recombination of 5.4 target gene pcr amplification products
The pcr amplification product of F1-fto and R1-fto is recombined into pGEM-T Easy carrier (reactions of 5 μ l total volumes),
Reaction composition are as follows:
1.5 μ l pcr amplification products (being derived from 5.5.2)
2.5μl 2×Ligation Buffer
0.5 μ l T4DNA ligase
0.5 μ l pGEM-T Easy carrier (Promega)
Reaction time are as follows: incubation at room temperature 60min
The conversion of 5.5 recons
By 100 μ l bacillus coli DH 5 alpha competent cell (pfu >=10 of above-mentioned 5 μ l connection product8) converted.Then
It is coated on the LB plate of benzyl containing ammonia (50 μ g/ml), is inverted overnight incubation at 37 DEG C.
5.6 target gene group DNA edit the recombination confirmation of sub (Edits)
According to stripe size, chooses clone and directly send sequencing, sequencing primer T7.Group 1 (sgRNA1, sgRNA3,
SgRNA5, sgRNA7) survey 10 is sent, sequencing result feeds back 10.Fig. 2 is shown in particular sequence comparison.Target gene group DNA is edited
Sub (Edits) sequence alignment result shows that sgRNA1, sgRNA3 are active, and sgRNA1 activity rate is 20%, sgRNA3 activity
Rate is 10%.1 (sgRNA2, sgRNA4, sgRNA6, sgRNA8) of group send survey 9, and sequencing result feeds back 9.Particular sequence ratio
To seeing Fig. 3.Target gene group DNA edit sub (Edits) sequence alignment result show sgRNA2, sgRNA4, sgRNA6,
SgRNA8 is inactive or active is lower than 5%.
6, conclusion:
In summary experimental result can be confirmed that the sgRNA1 and sgRNA3 can effectively guide Cas9 targeting cutting mesh
Mark gene.
2 zebra fish fto knock out mutants body production program of embodiment
(1) the just preparation for the person of building
By the method for 4 descriptions of scheme (two) in embodiment 1, zebra fish fertilized egg is collected according to a conventional method.It will be above-mentioned
After sgRNA1 and sgRNA3 (final concentration of 50ng/ μ l) and Cas9 albumen (final concentration of 200ng/ μ l) mix, micro- injection spot
Horse fish fertilized egg (injection volume is the every embryo of 1nl), prepares the person of building (Founder) at the beginning of fto knock out mutants body.
(2) screening of F1 mutant
1, prepared by F1 generation individual templet gene group DNA
Breeding and raising of the 1.1F1 for zebra fish
By the F0 embryonic feeder for having injected Cas9/sgRNA to sexal maturity, its pangamy is then enabled, F1 embryo is obtained.It will
F1 embryo routinely raises to sexal maturity, carries out genotype identification, screening-gene editor's mutant.
The 1.2 noninvasive materials of tissue
The F1 adult fish at 3~4 monthly ages is taken, clip part tail fin tissue is respectively put into 200 μ l PCR pipes, then in order
It is placed in and stores on ice.
1.3 genomic templates DNA preparation
The 10 μ l of YSY buffer that Nanjing Yao produces along Yu is added into the 200 μ l PCR pipes containing tail fin tissue.Quickly
After centrifugation, PCR pipe is put into PCR instrument, is reacted as follows: 65 DEG C of 30min, 95 DEG C of 5min, 16 DEG C of 1min, 4 DEG C.
2, the amplification of target gene group DNA
The genome sequence of 2.1 recognition sites containing sgRNA
Red font mark is used for the primer sequence of PCR amplification, the highlighted mark sgRNA recognition site sequence of yellow.
The design of 2.2 genomic fragment amplimers
F-fto-1:CAAAAACCAGTAGGTCTGTGGA
R-fto-1:GGCTGCAGGGTTCATGTAGT (RC:ACTACATGAACCCTGCAGCC)
2.3 genomic DNA fragment PCR amplifications
2.3.1 the composition of reaction
2 × Mastermix (Vazyme), 10 μ l, the ultrapure water of 7 μ l, 1 μ l forward and reverse (F-phf8-1 and R1R-phf8-
1) the cell genomic dna template of primer (5 μM) and 1 μ l obtained by 1.3.2 step.
2.3.2PCR reaction condition
95 DEG C of 3min, 35 × (95 DEG C of 30s, 56 DEG C of 30s, 72 DEG C of 50s), 72 DEG C of 10min, 4 DEG C.
3, the screening and identification of the F1 mutant of fto mutation allele is carried
It directly send the PCR product of fto mutant to sequencing, the mutation equipotential for confirming that its mutant carries is read by peak figure
The genotype of gene.
The confirmation of 3.1 mutant, 3 genotype
3.1.1 3 genotype of mutant and the truncated protein sequence of the mutation allele of prediction coding
3.1.2 peak figure (part) is sequenced
See Fig. 4.
The target gene group segment pcr amplification product direct Sequencing result figure (part) of Fig. 4 mutant 3
3.1.3 the truncated protein structural schematic diagram for the mutated gene coding predicted
See Fig. 5.
The confirmation of 3.2 mutant, 11 genotype
3.2.1 11 genotype of mutant and the truncated protein sequence of the mutation allele of prediction coding
3.2.2 peak figure (part) is sequenced
See Fig. 6.
The target gene group segment pcr amplification product direct Sequencing result figure (part) of Fig. 6 mutant 11
3.2.3 the truncated protein structural schematic diagram for the mutated gene coding predicted
See Fig. 7.
The truncated protein structural schematic diagram for the mutation allele predictive coding that Fig. 7 mutant 11 carries
The confirmation of 3.3 mutant, 13 genotype
3.3.1 13 genotype of mutant and the truncated protein sequence of the mutation allele of prediction coding
3.3.2 peak figure (part) is sequenced
See Fig. 8.
The target gene group segment pcr amplification product direct Sequencing result figure (part) of Fig. 8 mutant 13
3.3.3 the truncated protein structural schematic diagram for the mutated gene coding predicted
See Fig. 9.
The truncated protein structural schematic diagram for the mutation allele predictive coding that Fig. 9 mutant 13 carries
4, conclusion: the F1 mutation zebra fish that 3 tails carry fto frameshift mutation is screened altogether.Wherein No. 11 and No. 13 zebra fish
Mutation allele entrained by mutant is consistent.
3 zebra fish fto afunction of embodiment reduces the accumulation of fat
1, embryo prepares
The F1 generation heterozygote zebra fish culture for carrying fto mutation is only in Nanjing Yao Shunyu Biotechnology Co., Ltd zebra fish
In vertical cultivation unit, when its sexal maturity, enables F1 generation individual freedom mate, routinely collect fertilized eggs, all embryos and juvenile fish
Cultivation is at 28.5 DEG C of room temperature, for testing when embryonic development was to 4 days.
2, the preparation of oil red O
It is purchased from Sigma company, mother liquor is configured to 0.5% (w/v), and 0.5g oil red O is taken to be dissolved in 100ml isopropanol.
3, embryo fixes
Take 2g paraformaldehyde be dissolved in PBS in 65 DEG C of water-baths (76g NaCl, 9.9gNa2HPO4,3.6gNaH2PO4,
It is dissolved in 10L water, pH is adjusted to 7.0), be configured to 4%PFA, for fixing 4dpf embryo.
4, oil red O stain
1) 4 days zebra fish juvenile fish are taken, 4% 4 DEG C of paraformaldehyde fixes 12 hours
2) PBST is washed 2 times
3) 0.5% oil red O room temperature dyes 4-6 hours
4) PBST is washed 3 times, and 60% isopropanol is washed 2 times, every time 5 minutes
5) PBST is washed once, is observed under anatomical lens, digital camera photographs to record.
5, genotype identification and interpretation of result
To the ucp1 zebra fish mutant through oil red O stain, genome is extracted, by the scheme write listed by embodiment 2 to every
A embryo carries out genotype identification one by one.As a result, it has been found that the accumulation of embryo's fat of ucp1 homozygous mutation significantly reduces (Figure 10).
The zebra fish mutant prelarva inner lipid storage capacity that Figure 10 carries fto homozygous mutation is reduced.Oil red O is to development to 4
It zebra fish prelarva is dyed, and finds the ucp1 mutant zebra fish prelarva body fat compared with wild-type zebrafish
Content significantly reduces.
Claims (10)
1. the foundation and application of the human obesity zebra fish based on FTO gene, feature provide firstly two can be effective
The active sgRNA for guiding Cas9 identification zebra fish fto gene, the zebra fish for having made fto gene knockout using active sgRNA are prominent
Variant provides the zebra fish model as human obesity, thus establish zebra fish fto gene can be used as mark gene answer
For screening and establishing the novel drugs and new method for the treatment of human obesity.
2. feature as described in claim 1 can effectively guide Cas9 to identify that the active sgRNA of zebra fish fto gene is respectively
SgRNA1 and sgRNA3.
3. the feature as described in right 1, the mutant of zebra fish be respectively carry insertion 4bp and lack 4bp fto it is invalid etc.
The heterozygote of position gene, sexually matured heterozygote selfing generate zebra fish model of the homozygote as human obesity.
4. the zebra fish model as described in right 3, the age of zebra fish prelarva is after fertilization 3 days, 4 days, 5 days, 6 days and 7 days.
5. the zebra fish model as described in right 3, applied to screening and the novel drugs and new method of establishing treatment human obesity.
6. the feature as described in right 1, mark gene of the fto gene as human obesity, homozygous mutation lead to zebra fish
Prelarva Fat Accumulation is suppressed.
7. the feature as described in right 6, the novel drugs of the reduction instruction treatment human obesity of zebra fish fto gene expression dose
With the screening and foundation of new method.
8. the feature as described in right 6, zebra fish fto gene can carry out various gene modifications, include but are not limited to,
Fto knocks in fluorescent reporter gene in site, to indicate the reduction of fto gene expression, for screening and establishing treatment human obesity
Novel drugs and new method.
9. the feature as described in right 6, it includes but is not limited to fluorescence report that the regulating and controlling sequence of zebra fish fto gene, which can be used for driving,
Gene, with prepare transgenosis zebra fish, for screening and establishing the novel drugs and new method for the treatment of human obesity.
10. feature as described in claim 1, the fto gene that the fto gene of zebra fish can be other fish model animals is made
To identify gene, for screening and establishing the novel drugs and new method for the treatment of human obesity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710545564.7A CN109207524A (en) | 2017-06-29 | 2017-06-29 | The foundation and application of human obesity's zebra fish model based on FTO gene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710545564.7A CN109207524A (en) | 2017-06-29 | 2017-06-29 | The foundation and application of human obesity's zebra fish model based on FTO gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109207524A true CN109207524A (en) | 2019-01-15 |
Family
ID=64993606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710545564.7A Pending CN109207524A (en) | 2017-06-29 | 2017-06-29 | The foundation and application of human obesity's zebra fish model based on FTO gene |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109207524A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112094840A (en) * | 2019-06-17 | 2020-12-18 | 南京尧顺禹生物科技有限公司 | Rapid preparation method of trace animal sample genome DNA template for genome segment amplification |
| CN113897362A (en) * | 2021-08-31 | 2022-01-07 | 浙江赛微思生物科技有限公司 | Scn1lab gene knockout zebra fish epilepsy model and construction method and application thereof |
| CN114836476A (en) * | 2022-05-12 | 2022-08-02 | 上海交通大学医学院附属瑞金医院 | FTO rs1421085T > C point mutation mouse model and application thereof |
| CN114875073A (en) * | 2022-05-30 | 2022-08-09 | 中南大学湘雅医院 | Preparation method of zebra fish model for adolescent idiopathic scoliosis |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009098290A1 (en) * | 2008-02-06 | 2009-08-13 | Heinrich-Heine Universität Düsseldorf | Fto-modified non-human mammal |
| US20110123981A1 (en) * | 2007-04-03 | 2011-05-26 | Centre National De La Recherche Scientifique (Cnrs | Fto gene polymorphisms associated to obesity and/or type ii diabetes |
| CN105274144A (en) * | 2015-09-14 | 2016-01-27 | 徐又佳 | Preparation method of zebrafish with hepcidin gene knocked out by use of CRISPR / Cas9 technology |
| CN105594664A (en) * | 2016-02-16 | 2016-05-25 | 湖南师范大学 | Statla gene deletion type zebra fish |
| CN106047877A (en) * | 2016-06-24 | 2016-10-26 | 中山大学附属第医院 | Targeted-FTO-gene-knockout sgRNA (small guide ribonucleic acid) and CRISP (clustered regularly interspaced short palindromic repeats)/Cas9 slow virus system and application thereof |
| CN106636197A (en) * | 2016-09-22 | 2017-05-10 | 南京市妇幼保健院 | Method for directional knockdown of multi-copy gene in zebrafish genome |
-
2017
- 2017-06-29 CN CN201710545564.7A patent/CN109207524A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110123981A1 (en) * | 2007-04-03 | 2011-05-26 | Centre National De La Recherche Scientifique (Cnrs | Fto gene polymorphisms associated to obesity and/or type ii diabetes |
| WO2009098290A1 (en) * | 2008-02-06 | 2009-08-13 | Heinrich-Heine Universität Düsseldorf | Fto-modified non-human mammal |
| CN105274144A (en) * | 2015-09-14 | 2016-01-27 | 徐又佳 | Preparation method of zebrafish with hepcidin gene knocked out by use of CRISPR / Cas9 technology |
| CN105594664A (en) * | 2016-02-16 | 2016-05-25 | 湖南师范大学 | Statla gene deletion type zebra fish |
| CN106047877A (en) * | 2016-06-24 | 2016-10-26 | 中山大学附属第医院 | Targeted-FTO-gene-knockout sgRNA (small guide ribonucleic acid) and CRISP (clustered regularly interspaced short palindromic repeats)/Cas9 slow virus system and application thereof |
| CN106636197A (en) * | 2016-09-22 | 2017-05-10 | 南京市妇幼保健院 | Method for directional knockdown of multi-copy gene in zebrafish genome |
Non-Patent Citations (6)
| Title |
|---|
| ASHA SETH等: "he emerging use of zebrafish to model metabolic disease", 《DISEASE MODELS & MECHANISMS》 * |
| DANIEL P S OSBORN等: "Loss of FTO antagonises Wnt signaling and leads to developmental defects associated with ciliopathies", 《PLOS ONE》 * |
| 杨凤娇等: "FTO基因:肥胖治疗的新靶标", 《中国新药与临床杂志》 * |
| 王彦芹 等: "《现代分子生物学实验指导》", 31 March 2017, 西安交通大学出版社 * |
| 胡依萌等: "CRISPR/Cas9技术在代谢性疾病研究中的应用进展", 《山东医药》 * |
| 董润安 等: "《光敏化氧化反应的化学生物学》", 30 June 2016, 北京理工大学出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112094840A (en) * | 2019-06-17 | 2020-12-18 | 南京尧顺禹生物科技有限公司 | Rapid preparation method of trace animal sample genome DNA template for genome segment amplification |
| CN113897362A (en) * | 2021-08-31 | 2022-01-07 | 浙江赛微思生物科技有限公司 | Scn1lab gene knockout zebra fish epilepsy model and construction method and application thereof |
| CN114836476A (en) * | 2022-05-12 | 2022-08-02 | 上海交通大学医学院附属瑞金医院 | FTO rs1421085T > C point mutation mouse model and application thereof |
| CN114875073A (en) * | 2022-05-30 | 2022-08-09 | 中南大学湘雅医院 | Preparation method of zebra fish model for adolescent idiopathic scoliosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cui et al. | Genome editing reveals dmrt1 as an essential male sex-determining gene in Chinese tongue sole (Cynoglossus semilaevis) | |
| WO2018177351A1 (en) | Method for preparing non-chimeric gene knockout animal based on crispr/cas9 technology | |
| CN109207524A (en) | The foundation and application of human obesity's zebra fish model based on FTO gene | |
| Wang et al. | Genomic basis of striking fin shapes and colors in the fighting fish | |
| CN108531487A (en) | The preparation method and application of humanization SIRPA genetic modification animal models | |
| Horie et al. | Investigation of Oxtr-expressing neurons projecting to nucleus accumbens using Oxtr-ires-Cre knock-in prairie voles (Microtus ochrogaster) | |
| Barske et al. | Evolution of vertebrate gill covers via shifts in an ancient Pou3f3 enhancer | |
| Luo et al. | GLIS1, a potential candidate gene affect fat deposition in sheep tail | |
| JPWO2003004637A1 (en) | Use of histamine receptor H3 gene involved in regulation of body weight or food intake | |
| CN113699152A (en) | Construction method and application of SLC35E2B gene knockout mouse animal model | |
| CN106521638A (en) | Resource library of rat with gene mutation and preparation method thereof | |
| Huang et al. | Single nucleotide polymorphisms in the chicken Lmbr1 gene are associated with chicken polydactyly | |
| Sasado et al. | Mutation in cpsf6/CFIm68 (cleavage and polyadenylation specificity factor subunit 6) causes short 3'UTRs and disturbs gene expression in developing embryos, as revealed by an analysis of primordial germ cell migration using the medaka mutant naruto | |
| CN107955818B (en) | Establishing method and application of non-human primate animal model with neurological diseases | |
| Moreno et al. | Comparative genomics for detecting human disease genes | |
| CN109207523A (en) | The foundation and application of human obesity's zebra fish model based on UCP1 gene | |
| CN112626122A (en) | hKDR humanized mouse model and establishing method and application thereof | |
| Chen et al. | Genome-Wide Association study reveals SNPs and candidate genes related to growth and body shape in Bighead carp (Hypophthalmichthys nobilis) | |
| CN111019972A (en) | Construction method and application of CD27 humanized mouse model | |
| Sun et al. | Study on sex-linked region and sex determination candidate gene using a high-quality genome assembly in yellow drum | |
| Yuan et al. | Heart enhancers with deeply conserved regulatory activity are established early in development | |
| US20090119786A1 (en) | Model animal of schizophrenia | |
| CN114747541B (en) | Construction method and application of PSGL-1 humanized non-human animal model | |
| CN114410691B (en) | Construction method and application of SLC35E1 gene knockout mouse animal model | |
| CN111808859B (en) | gRNA of WAS gene and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190115 |
|
| WD01 | Invention patent application deemed withdrawn after publication |